Trypto Therapeutics GmbH

TRYPTO THERAPEUTICS is developing a set of novel, proprietary small molecules to treat serotonin-related diseases. Our next-generation TPH1 inhibitors differ in scaffold, binding mode, and potency from any TPH inhibitors currently on the market or under clinical investigation, offering a truly differentiated therapeutic approach.

The Problem

Pathologically high serotonin levels — driven by the enzyme Tryptophan Hydroxylase 1 (TPH1) — contribute to tumor growth and metastasis in colorectal cancer, severe symptoms in neuroendocrine tumor patients (Carcinoid Syndrome), pulmonary vessel remodeling in PAH, inflammatory diseases including asthma and IBD, and fibrotic changes in lungs, liver, skin, and kidneys. Existing TPH1 inhibitors are insufficient in potency and fail to address the full spectrum of these diseases.

The Solution

Trypto Therapeutics has developed a patented novel class of TPH1 inhibitors (TPHi) with nanomolar potency in vitro, binding to the Trp (substrate) and BH4 (co-factor) binding pockets of TPH1 simultaneously. The lead TPHi compound has achieved readiness to transition from academic research towards targeted pharmaceutical development, with a comprehensive data package covering potency, selectivity, ADME/TOX, in vivo PK/PD, and a fully established, scalable CMC process.